Literature DB >> 14993463

Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.

Roy Fleischmann1, Dave Shealy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14993463     DOI： 10.1124/mi.3.6.310

Source DB:  PubMed          Journal:  Mol Interv        ISSN： 1534-0384


× No keyword cloud information.
  5 in total

1.  Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis.

Authors:  Canan Aybay; Sumru Ozel; Cemalettin Aybay
Journal:  Rheumatol Int       Date:  2005-12-09       Impact factor: 2.631

Review 2.  The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists.

Authors:  Adel Alawadhi; Khaldoon Alawneh; Zeyad Ahmed Alzahrani
Journal:  Clin Rheumatol       Date:  2012-08-09       Impact factor: 2.980

Review 3.  Certolizumab pegol.

Authors:  Niti Goel; Sue Stephens
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

4.  Treatment of Autoimmune Hepatitis: Current and Future Therapies.

Authors:  Fernando Alvarez
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

5.  Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?

Authors:  Hsin-Hua Chen; Der-Yuan Chen; Yi-Ming Chen; Chao-Hsiun Tang
Journal:  Patient Prefer Adherence       Date:  2016-02-05       Impact factor: 2.711
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.